A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 28
Summary
- Conditions
- Hairy Cell Leukemia
- Leukemia
- Leukemia, Hairy Cell
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03410875
- Collaborators
- Dana-Farber Cancer Institute
- Yale University
- Investigators
- Principal Investigator: Jae Park, MD Memorial Sloan Kettering Cancer Center